Larimar Therapeutics (FRA:ZA71) Tariff Resilience Score: 4/10 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:ZA71 Larimar Therapeutics Inc FRA:ZA71
40 GF Score
Price €3.62
! 2 Warning Signs
View Full Analysis

What is Larimar Therapeutics Tariff Resilience Score?

Larimar Therapeutics FRA:ZA71 +2.84% 40 Tariff Resilience Score is 4 as of Jul. 14, 2026. GuruFocus rates FRA:ZA71 with a GF Score™ of 40/100. The stock has 2 warning signs investors should review. Among 1,370 Biotechnology companies, Larimar Therapeutics ranks better than 52.48% on this metric.

Larimar Therapeutics has the Tariff Resilience Score of 4, which implies that the company might have Average Resilient.

Larimar Therapeutics has High dependency on international supply chains for raw materials. Limited pricing power and lack of alternative suppliers increase vulnerability. Previous tariff changes have impacted costs.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Larimar Therapeutics might have Average Resilient.

Larimar Therapeutics  (FRA:ZA71) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Larimar Therapeutics Tariff Resilience Score Related Terms

FRA:ZA71 vs XFOR, CMPX, PROK: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Larimar Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Larimar Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Larimar Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Larimar Therapeutics's Tariff Resilience Score falls into.


FRA:ZA71
40GF Score
Larimar Therapeutics Inc FRA:ZA71
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 4 mean?
Larimar Therapeutics (FRA:ZA71) has a Tariff Resilience Score of 4 as of Jul. 14, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Larimar Therapeutics ranks #651 out of 1370 companies in the Biotechnology industry, placing it in the top 47.5%.
Is Larimar Therapeutics' Tariff Resilience Score too high?
Larimar Therapeutics' current Tariff Resilience Score is 4. The Biotechnology industry median Tariff Resilience Score is 4.00. Larimar Therapeutics' value of 4 is 0% at this industry median. Based on the distribution chart, Larimar Therapeutics ranks #651 out of 1370 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Larimar Therapeutics has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Larimar Therapeutics' Tariff Resilience Score compare to XFOR and CMPX?
According to the Biotechnology industry distribution chart, Larimar Therapeutics ranks #651 out of 1370 companies for Tariff Resilience Score. This puts Larimar Therapeutics in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Larimar Therapeutics' value of 4 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Larimar Therapeutics's current Tariff Resilience Score of 4 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Larimar Therapeutics's current Tariff Resilience Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Larimar Therapeutics stock overvalued right now?
Larimar Therapeutics (FRA:ZA71) has a current Tariff Resilience Score of 4. The current Tariff Resilience Score is 4 and 0% at the Biotechnology industry median of 4.00. Larimar Therapeutics' overall GF Score™ is 40/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Larimar Therapeutics (FRA:ZA71), the current Tariff Resilience Score is 4 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Larimar Therapeutics Business Description

Other Exchanges LRMR:USA
Address Three Bala Plaza East, Suite 506, Bala Cynwyd, PA, USA, 19004
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
40GF Score

Get the complete analysis for FRA:ZA71

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.62
Price